Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy-Reference-Cited by-同舟云学术

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

Published:2016 Issue:6 Volume:1 Page:e000118
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Manegold Christian,Adjei Alex,Bussolino Federico,Cappuzzo Federico,Crino Lucio,Dziadziuszko Rafal,Ettinger David,Fennell Dean,Kerr Keith,Le Chevalier Thierry,Leighl Natasha,Papotti Mauro,Paz-Ares Luis,Pérol Maurice,Peters Solange,Pirker Robert,Quoix Elisabeth,Reck Martin,Smit Egbert,Vokes Everett,van Zandwijk Nico,Zhou Caicun

Funder

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference54 articles.

1. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women;Lortet-Tieulent;Lung Cancer,2014

2. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Peters;Ann Oncol,2012

3. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003;Yang;Chest,2005

4. The changing epidemiology of lung cancer in Europe;Janssen-Heijnen;Lung Cancer,2003

5. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer;Schiller;N Engl J Med,2002

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved semi-parametric inference for a mixture model of responses from a control versus treatment group trial;Statistical Methods in Medical Research;2024-02-23

2. Statistical Inference for Method of Moments Estimators of a Semi-Supervised Two-Component Mixture Model;The American Statistician;2022-09-14

3. Sample size calculations for mixture alternatives in a control group vs. treatment group design;Statistics;2020-01-02

4. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?;Future Oncology;2019-04

5. Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015;PLOS ONE;2019-02-22